Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-analysis
Open accessThe DOI matches its Crossref record; 105 of the 106 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A growing body of evidence has suggested that metformin potentially reduces the risk of cancer. Our objective was to enhance the precision of estimates of the effect of metformin on the risk of any-site and site-specific cancers in patients with diabetes. METHODS/PRINCIPAL FINDINGS: We performed a search of MEDLINE, EMBASE, ISI Web of Science, Cochrane Library, and ClinicalTrials.gov for pertinent articles published as of October 12, 2011, and included them in a systematic review and meta-analysis. We calculated pooled risk ratios (RRs) for overall cancer mortality and cancer incidence. Of the 21,195 diabetic patients reported in 6 studies (4 cohort studies, 2 RCTs), 991 (4.5%) cases of death from cancer were reported. A total of 11,117 (5.3%) cases of incident cancer at any site were reported among 210,892 patients in 10 studies (2 RCTs, 6 cohort studies, 2 case-control studies). The risks of cancer among metformin users were significantly lower than those among non-metformin users: the pooled RRs (95% confidence interval) were 0.66 (0.49-0.88) for cancer mortality, 0.67 (0.53-0.85) for all-cancer incidence, 0.68 (0.53-0.88) for colorectal cancer (n = 6), 0.20 (0.07-0.59) for hepatocellular cancer (n = 4), 0.67 (0.45-0.99) for lung cancer (n = 3). CONCLUSION/SIGNIFICANCE: The use of metformin in diabetic patients was associated with significantly lower risks of cancer mortality and incidence. However, this analysis is mainly based on observational studies and our findings underscore the more need for long-term RCTs to confirm this potential benefit for individuals with diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Metformin may also confer a decreased cancer risk in patients with diabetes (90).”
From Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity (2015) · cites this paper as [90]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164 · cited 1×
“All the procedures were in accordance with the guidelines for the Quality of Reporting of Meta-analyses [24], the meta-analysis of observational studies in epidemiology [25] and the PRISMA statement [26].”
MethodDermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.11.008 · Cited by 17,893
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010 · Cited by 17,796
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00136 · Cited by 10,349
Lopez, A. D., Mathers, C. D., Ezzati, M., Jamison, D. T., & Murray, C. J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68770-9 · Cited by 5,630 · cited 1×
“In light of the fact that cancer is the second and diabetes the twelfth leading cause of death worldwide [59] and that the number of people with diabetes is”
Background
Cited by
Items 101–200 of 580
Joung, K. H., Jeong, J., & Ku, B. J. (2015) · BioMed Research International · doi:10.1155/2015/920618 · Cited by 100
“[171] H.”
BackgroundEffects of Metformin on CD133+ Colorectal Cancer Cells in Diabetic Patients
Zhang, Y., Guan, M., Zheng, Z., Zhang, Q., Gao, F., & Xue, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081264 · Cited by 83
Zhang, T., Guo, P., Zhang, Y., Xiong, H., Yu, X., Xu, S., Wang, X., He, D., & Jin, X. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141224603 · Cited by 85
“antidiabetic agents [15,16].”
Kasuga, M., Ueki, K., Tajima, N., Noda, M., Ohashi, K., Noto, H., Goto, A., Ogawa, W., Sakai, R., Tsugane, S., et al. (2013) · Cancer Science · doi:10.1111/cas.12203 · Cited by 89
Self-citationMetformin prevents cell tumorigenesis through autophagy-related cell death
Santi, M. D., Baldelli, G., Diotallevi, A., Galluzzi, L., Schiavano, G. F., & Brandi, G. (2019) · Scientific Reports · doi:10.1038/s41598-018-37247-6 · Cited by 83
Angiogenesis and cancer stem cells: New perspectives on therapy of ovarian cancer
Markowska, A., Sajdak, S., Markowska, J., & Huczyński, A. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.06.030 · Cited by 82
Kaneto, H., Kimura, T., Obata, A., Shimoda, M., & Kaku, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052596 · Cited by 90
Cancer Risk in HBV Patients With Statin and Metformin Use: A Population-Based Cohort Study
Chen, C.-I., Kuan, C.-F., Fang, Y.-A., Liu, S.-H., Liu, J.-C., Wu, L.-L., Chang, C.-J., Yang, H.-C., Hwang, J., Miser, J. S., et al. (2015) · Medicine · doi:10.1097/md.0000000000000462 · Cited by 77
Clinical management of obese patients with cancer
Tao, W., & Lagergren, J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.120 · Cited by 83
Yu, H., Yin, L., Jiang, X., Sun, X., Wu, J., Tian, H., Gao, X., & He, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0116327 · Cited by 77
Metformin in Lung Cancer: Review of in Vitro and in Vivo Animal Studies
Yousef, M., & Tsiani, E. (2017) · Cancers · doi:10.3390/cancers9050045 · Cited by 77
Haikala, H. M., Anttila, J. M., Marques, E., Raatikainen, T., Ilander, M., Hakanen, H., Ala-Hongisto, H., Savelius, M., Balboa, D., Von Eyss, B., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08541-2 · Cited by 75
Diabetes Mellitus and Risk of Bladder Cancer: A Meta-Analysis of Cohort Studies
Zhu, Z., Zhang, X., Shen, Z., Zhong, S., Wang, X., Lu, Y., & Chen, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056662 · Cited by 75
“Metformin therapy in diabetic patients appears to be associated with a significantly lower risk of cancer incidence and mortality [55,56,57].”
BackgroundIncidence of Bladder Cancer in Patients With Type 2 Diabetes Treated With Metformin or Sulfonylureas
Mamtani, R., Pfanzelter, N., Haynes, K., Finkelman, B. S., Wang, X., Keefe, S. M., Haas, N. B., Vaughn, D. J., & Lewis, J. D. (2014) · Diabetes Care · doi:10.2337/dc13-1489 · Cited by 71
A new classification of cardio-oncology syndromes
de Boer, R. A., Aboumsallem, J. P., Bračun, V., Leedy, D. J., Cheng, R. K.-H., Patel, S., Rayan, D., Zaharova, S., Rymer, J. A., Kwan, J. M., et al. (2021) · Cardio-Oncology · doi:10.1186/s40959-021-00110-1 · Cited by 79
Amin, S., Mhango, G., Lin, J., Aronson, A., Wisnivesky, J., Boffetta, P., & Lucas, A. L. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.288 · Cited by 68
“Furthermore, diabetic patients with cancer tend to have worse survival, and metformin has been shown to both decrease the risk of cancer and improve survival among diabetics with cancer (3,4,10– 12).”
Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer
Häggström, C., Hemelrijck, M. V., Zethelius, B., Robinson, D., Grundmark, B., Holmberg, L., Guðbjörnsdóttir, S., Garmo, H., & Stattin, P. E. (2016) · International Journal of Cancer · doi:10.1002/ijc.30480 · Cited by 71
Diabetes, Glycated Hemoglobin, and Risk of Cancer in the UK Biobank Study
Peila, R., & Rohan, T. E. (2020) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-19-1623 · Cited by 70
“Studies of the association between diabetic medications and cancer risk have shown evidence of altered risk of cancer depending on the type ofmedications and the cancer (43).”
BackgroundInsulin Resistance: Any Role in the Changing Epidemiology of Thyroid Cancer?
Malaguarnera, R., Vella, V., Nicolosi, M. L., & Belfiore, A. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00314 · Cited by 69
“Similar reductions in cancer risk and mortality was also observed in a second meta-analysis that included 32 articles (276).”
ResultRecent Advances in the Use of Metformin: Can Treating Diabetes Prevent Breast Cancer?
Hatoum, D., & McGowan, E. M. (2015) · BioMed Research International · doi:10.1155/2015/548436 · Cited by 66
“Five recent reports, one comprised of a metaanalysis of twenty-one observational studies subgrouped by cancer type, did not show any significant reduction in mortality in breast cancer patients [105–107, 116, 117].”
Use of metformin and risk of kidney cancer in patients with type 2 diabetes
Tseng, C. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.09.027 · Cited by 69
Wang, L., Li, Y., Yu, L., Zhang, X., Zhao, L., Gong, F., Yang, X., & Guo, X. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114113 · Cited by 69
Sandulache, V. C., Hamblin, J. S., Skinner, H. D., Kubik, M. W., Myers, J. N., & Zevallos, J. P. (2013) · Head & Neck · doi:10.1002/hed.23409 · Cited by 66
“66).(10) Disease-specific retrospective studies have shown improved survival associated with metformin use in lung, colorectal cancer, and pancreatic cancer and improved response to treatment in rectal and breast cancer.”
BackgroundThe Effects of Metformin on Ovarian Cancer
Dilokthornsakul, P., Chaiyakunapruk, N., Termrungruanglert, W., Pratoomsoot, C., Saokaew, S., & Sruamsiri, R. (2013) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e3182a80a21 · Cited by 67
“Moreover, in terms of preventive effects, our results were also similar to previous studies(28,29) that showed the effects of metformin on preventing occurrence of any cancer such as hepatocellular cancer, colorectal cancer, and lung cancer.(28,29) The anticancer effect of metformin has been attributed to several mech…”
ResultIkhlas, S., & Ahmad, M. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.07.029 · Cited by 71
Suppression of PDHX by microRNA-27b deregulates cell metabolism and promotes growth in breast cancer
Eastlack, S. C., Dong, S., Ivan, C., & Alahari, S. K. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0851-8 · Cited by 71
“cancer risk in diabetic patients using it to control hyperglycemia [50, 51].”
Kim, H. J., Lee, S., Chun, K. H., Jeon, J. Y., Han, S. J., Kim, D. J., Kim, Y. S., Woo, J.-T., Nam, M.-S., Baik, S. H., et al. (2018) · Medicine · doi:10.1097/md.0000000000010036 · Cited by 62
Murff, H. J., Roumie, C. L., Greevy, R. A., Hackstadt, A. J., McGowan, L. D., Hung, A. M., Grijalva, C. G., & Griffin, M. R. (2018) · Cancer Causes & Control · doi:10.1007/s10552-018-1058-4 · Cited by 72
Ochoa-González, F. D. L., Cervantes-Villagrana, A. R., Fernández-Ruiz, J. C., Nava-Ramirez, H. S., Hernandez-Correa, A. C., Enciso‐Moreno, J. A., & Castañeda‐Delgado, J. E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150900 · Cited by 70
“The widespread use of this drug in diabetes treatment has been linked to reduced incidence of several types of cancer for their reported effect on cancer cell proliferation [16, 26, 28, 29].”
BackgroundDutkowska, A., & Antczak, A. J. (2016) · Advances in respiratory medicine · doi:10.5603/piap.2016.0022 · Cited by 62
Roles of microbiota in response to cancer immunotherapy
Inamura, K. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.026 · Cited by 65
Veeramachaneni, R., Yu, W., Newton, J. M., Kemnade, J. O., Skinner, H. D., Sikora, A. G., & Sandulache, V. C. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002773 · Cited by 64
Repurposing old drugs to chemoprevention: the case of metformin
Heckman‐Stoddard, B. M., Gandini, S., Puntoni, M., Dunn, B. K., DeCensi, A., & Szabo, E. M. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.009 · Cited by 66
“Multiple metaanalyses have now reported a decrease in cancer incidence of approximately 14%–40%, along with a decrease in mortality in the same range (Table 1) [45–50].”
BackgroundDiabetes Mellitus and Colorectal Cancer Risk
Kallergi, A., Chambre, C., Duchemann, B., Fysekidis, M., & Bihan, H. (2015) · Current Colorectal Cancer Reports · doi:10.1007/s11888-015-0274-5 · Cited by 62
Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice
Tajima, K., Nakamura, A., Shirakawa, J., Togashi, Y., Orime, K., Sato, K., Inoue, H., Kaji, M., Sakamoto, E., Ito, Y., et al. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00133.2013 · Cited by 59
“Epidemiological studies have shown that metformin treatment is associated with a significantly lower risk of cancer mortality and development (7, 26, 43).”
BackgroundEssential roles of mitochondrial and heme function in lung cancer bioenergetics and tumorigenesis
Kalainayakan, S. P., FitzGerald, K. E., Konduri, P. C., Vidal, C., & Li, Z. (2018) · Cell & Bioscience · doi:10.1186/s13578-018-0257-8 · Cited by 63
Hepatoprotective activity of metformin: A new mission for an old drug?
Iranshahy, M., Rezaee, R., & Karimi, G. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.02.004 · Cited by 63
Qi, X., Xu, W., Xie, J., Wang, Y., Han, S., Wei, Z., Ni, Y., Dong, Y., & Han, W. (2016) · Scientific Reports · doi:10.1038/srep35788 · Cited by 65
Varghese, S., Samuel, S. M., Varghese, E., Kubatka, P., & Büsselberg, D. (2019) · Biomolecules · doi:10.3390/biom9010016 · Cited by 63
“Multiple reports have supported the connection between metformin, diabetes, and breast cancer [21,41,42].”
BackgroundNojima, I., Eikawa, S., Tomonobu, N., Hada, Y., Kajitani, N., Teshigawara, S., Miyamoto, S., Tone, A., Uchida, H. A., Nakatsuka, A., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-71946-3 · Cited by 66
Molecular targets of metformin antitumor action
Sośnicki, S., Kapral, M., & Węglarz, L. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2016.04.021 · Cited by 59
Diabetes-Related Dysfunction of the Small Intestine and the Colon: Focus on Motility
Horváth, V. J., Putz, Z., Izbéki, F., Körei, A. E., Gerő, L., Lengyel, C., Kempler, P., & Várkonyi, T. T. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0672-8 · Cited by 58
Dual Blockade of Lactate/GPR81 and PD-1/PD-L1 Pathways Enhances the Anti-Tumor Effects of Metformin
Chen, S., Zhou, X., Yang, X., Li, W., Li, S., Hu, Z., Chen, L., Shi, R., Liu, J., Chen, G., et al. (2021) · Biomolecules · doi:10.3390/biom11091373 · Cited by 62
Metformin does not alter the risk of lung cancer: A case–control analysis
Bodmer, M., Becker, C., Jick, S. S., & Meier, C. R. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.08.010 · Cited by 58
Metformin may reduce bladder cancer risk in Taiwanese patients with type 2 diabetes
Tseng, C. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0562-6 · Cited by 57
“[34] showed a pooled risk ratio for bladder cancer (95 % confidence interval) of 0.”
BackgroundGong, J., Kelekar, G., Shen, J., Shen, J., Kaur, S., & Mita, M. M. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0423-z · Cited by 60
de Bruijn, K. M. J., Ruiter, R., de Keyser, C. E., Hofman, A., Stricker, B. H. C., & van Eijck, C. H. J. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.06.019 · Cited by 62
The protective potential of metformin against acetaminophen-induced hepatotoxicity in BALB/C mice
Saravi, S. S. S., Hasanvand, A., Shahkarami, K., & Dehpour, A. R. (2016) · Pharmaceutical Biology · doi:10.1080/13880209.2016.1185633 · Cited by 56
“Epidemiological studies have suggested that metformin significantly improves the viability of hepatocytes in fatty livers including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitits (NASH) as well as hepatocarcinoma (Noto et al. 2012).”
BackgroundPan, X., He, M., Yu, C., Lv, J., Guo, Y., Bian, Z., Yang, L., Chen, Y., Wu, T., Chen, Z., et al. (2017) · American Journal of Epidemiology · doi:10.1093/aje/kwx376 · Cited by 58
“Consistently, 2 systematic reviews showed that metformin reduced subsequent cancer risk after diabetes diagnosis (27, 28).”
The Effect of Metformin on Mortality Following Cancer among Patients with Diabetes
Lega, I. C., Shah, P. S., Margel, D., Beyene, J., Rochon, P. A., & Lipscombe, L. L. (2014) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0327 · Cited by 53
“org Cancer Epidemiol Biomarkers Prev; 23(10) October 2014 1979”
BackgroundInfluentialMetformin and cancer in type 2 diabetes: a systematic review and comprehensive bias evaluation
Farmer, R. E., Ford, D., Forbes, H. J., Chaturvedi, N., Kaplan, R. S., Smeeth, L. L., & Bhaskaran, K. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw275 · Cited by 60
Saito, A., Kitayama, J., Horie, H., Koinuma, K., Ohzawa, H., Yamaguchi, H., Kawahira, H., Mimura, T., Lefor, A. K., & Sata, N. (2020) · Cancer Science · doi:10.1111/cas.14615 · Cited by 56
Diabetes and pancreatic cancer.
Muniraj, T., & Chari, S. T. (2012) · PubMed · Cited by 71
Contributions of AMPK and p53 dependent signaling to radiation response in the presence of metformin
Muaddi, H., Chowdhury, S., Vellanki, R. N., Zamiara, P., & Koritzinsky, M. (2013) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.06.014 · Cited by 52
“This interest originates from several epidemiological studies demonstrating a lower cancer incidence in diabetic patients taking metformin than in the general diabetic population [3].”
BackgroundMetformin and Thyroid: An Update
Pappa, T., & Alevizaki, M. (2013) · European Thyroid Journal · doi:10.1159/000346248 · Cited by 48
Sui, X., Xu, Y., Yang, J., Fang, Y., Lou, H., Han, W., Zhang, M., Chen, W., Wang, K., Li, D., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097781 · Cited by 52
“There is increasing evidence linking diabetes mellitus with an increased risk of colorectal cancer [5,6].”
BackgroundMetformin decreases lung cancer risk in diabetic patients in a dose-dependent manner
Tsai, M., Yang, C., Kung, Y.-T., Sheu, C., Shen, Y., Chang, P., Huang, M., & Chiu, H. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.09.012 · Cited by 52
Senolytics: Potential for Alleviating Diabetes and Its Complications
Palmer, A. K., Tchkonia, T., & Kirkland, J. L. (2021) · Endocrinology · doi:10.1210/endocr/bqab058 · Cited by 46
“In addition, metformin is known to alleviate diabetic complications and metabolic syndrome, and may confer lower cancer risk in diabetic patients (63).”
BackgroundChanges in sedentary behaviours across the retirement transition: a systematic review
Sprod, J. A., Ferrar, K., Olds, T., & Maher, C. A. (2015) · Age and Ageing · doi:10.1093/ageing/afv140 · Cited by 56
The Impact of Metformin on Tumor-Infiltrated Immune Cells: Preclinical and Clinical Studies
Abdelmoneim, M., Aboalela, M. A., Naoe, Y., Matsumura, S., Eissa, I. R., Bustos‐Villalobos, I., Sibal, P. A., Takido, Y., Kodera, Y., & Kasuya, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713353 · Cited by 51
“Moreover, several epidemiological studies showed that metformin has anticancer effects besides its glycemic control in T2DM, which enhances the need to understand the anticancer mechanisms of this drug [10,11].”
BackgroundKowall, B., Rathmann, W., & Kostev, K. (2014) · Diabetes Care · doi:10.2337/dc14-0977 · Cited by 51
“reduction in cancer mortality were reported (7).”
Carbon Source and Myc Expression Influence the Antiproliferative Actions of Metformin
Javeshghani, S., Zakikhani, M., Austin, S., Bazile, M., Blouin, M.-J., Topisirovic, I., St-Pierre, J., & Pollak, M. N. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2907 · Cited by 46
“Some pharmacoepidemiologic studies have suggested that metformin may have antineoplastic activity (21-27) but others have not supported this view (28-31).”
BackgroundNie, Z., Zhu, H., & Gu, M. (2016) · Pharmaceutical Biology · doi:10.1080/13880209.2016.1176057 · Cited by 53
“Several meta-analyses were conducted to evaluate the relationship, while the tissue still remains controversial (Decensi et al. 2010; Zhang et al. 2011; Noto et al. 2012; Soranna et al. 2012; Gandini et al. 2014).”
MethodWANG, J., Gao, Q., Wang, D., WANG, Z., & Chun, H. (2015) · Oncology Letters · doi:10.3892/ol.2015.3450 · Cited by 49
“Collated evidence from a number of clinical studies has recently been published in a meta-analysis (11).”
Cardel, M., Jensen, S. M., Pottegård, A., Jørgensen, T. L., & Hallas, J. (2014) · Cancer Medicine · doi:10.1002/cam4.306 · Cited by 46
“Several experimental studies have shown that metformin is likely to have anticancerous effects in both in vivo and in vitro settings [3–5].”
BackgroundIncrease in apoptosis by combination of metformin with silibinin in human colorectal cancer cells
Tsai, C.-C., Chuang, T.-W., Chen, L.-J., Niu, H.-S., Chung, K.-M., Cheng, J.-T., & Lin, K.-C. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i14.4169 · Cited by 47
Ahmed, I., Ferro, A., Cohler, A., Langenfeld, J. E., Surakanti, S. G., Aisner, J., Zou, W., Haffty, B. G., & Jabbour, S. K. (2015) · PubMed Central · doi:10.3978/j.issn.2072-1439.2014.12.32 · Cited by 49
Metformin for cancer prevention: a reason for optimism
Chan, A. T. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00006-1 · Cited by 47
Chen, H.-H., Lin, M., Muo, C., Yeh, S.-Y., Sung, F., & Kao, C. (2015) · Medicine · doi:10.1097/md.0000000000001013 · Cited by 46
“Metformin significantly reduced the risk of colorectal cancer, liver tumors, and lung cancer.(27) One article stated that DM patients treated with metformin were associated with an estimated 70% reduction in HCC risk.”
BackgroundRepurposing metabolic regulators: antidiabetic drugs as anticancer agents
Dhas, Y., Biswas, N., Divyalakshmi, M. R., Jones, L., & Ashili, S. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00204-z · Cited by 47
“Observational studies suggest that metformin use is linked to reduced cancer risk and decreased cancer-related and all-cause mortality [84, 85].”
BackgroundTroncone, M. J., Cargnelli, S., Villani, L. A., Isfahanian, N., Broadfield, L. A., Zychla, L., Wright, J., Pond, G. R., Steinberg, G. R., & Tsakiridis, T. K. (2017) · Oncotarget · doi:10.18632/oncotarget.17496 · Cited by 47
“Reduced incidence of NSCLC was also reported with metformin in type II diabetic patient in some [128, 130, 132] but not all studies [133] (Table 2).”
ResultBaglia, M. L., Cui, Y., Zheng, T., Yang, G., Li, H., You, M., Xu, L., Murff, H. J., Gao, Y., Zheng, W., et al. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2017.591 · Cited by 47
Old drugs, new uses: Drug repurposing in hematological malignancies
Kale, V. P., Habib, H., Chitren, R. J., Patel, M., Pramanik, K. C., Jonnalagadda, S. C., Challagundla, K. B., & Pandey, M. K. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.03.005 · Cited by 53
Cho, M. H., Yoo, T. G., Jeong, S., & Shin, D. W. (2020) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-20-0123 · Cited by 47
Kato, K., Iwama, H., Yamashita, T., Kobayashi, K., Fujihara, S., Fujimori, T., Kamada, H., Kobara, H., & Masaki, T. (2015) · Oncology Reports · doi:10.3892/or.2015.4496 · Cited by 45
“For instance, it is reported that patients with type 2 diabetes who are prescribed metformin have a lower risk of cancer compared to patients who do not take metformin (2).”
BackgroundLin, J., Gill, A. A., Zahm, S. H., Carter, C. A., Shriver, C. D., Nations, J. A., Anderson, W. F., McGlynn, K. A., & Zhu, K. (2017) · International Journal of Cancer · doi:10.1002/ijc.30724 · Cited by 46
“There is epidemiologic evidence that metformin may be associated with decreased cancer incidence.(10) A recent review and meta-analysis reported a 31% reduction in cancer incidence among metformin users, while some methodological issues remained.”
BackgroundChen, Y., Mushashi, F., Son, S., Bhatti, P., Dummer, T., & Murphy, R. A. (2023) · Scientific Reports · doi:10.1038/s41598-023-38431-z · Cited by 51
Michel, D. L., Gaunt, M. C., Arnason, T., & El‐Aneed, A. (2014) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2014.12.012 · Cited by 45
Salehi‐Abargouei, A., Ghiasvand, R., & Hariri, M. (2017) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-016-9248-4 · Cited by 46
AMP-Activated Protein Kinase: Friend or Foe in Cancer?
Vara‐Ciruelos, D., Dandapani, M., & Hardie, D. G. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033619 · Cited by 43
“In addition, following the discovery of the link between LKB1 and AMPK, the use of the AMPK activator metformin (Zhou et al. 2001) to treat type 2 diabetes was found to be associated with a reduced risk of cancer compared with other medications (Evans et al. 2005, Noto et al. 2012).”
BackgroundRepurposing metformin for the treatment of gastrointestinal cancer
Júnior, A. D. D. C., Bragagnoli, A. S. C., Costa, F. O., & Carvalheira, J. B. C. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i17.1883 · Cited by 46
Drug repositioning in drug discovery of T2DM and repositioning potential of antidiabetic agents
Zhu, S., Bai, Q., Li, L., & Xu, T. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.05.057 · Cited by 47
Metformin and lung cancer risk of patients with type 2 diabetes mellitus: A meta-analysis
ZHU, N., ZHANG, Y., GONG, Y., HE, J., & CHEN, X. (2015) · Biomedical Reports · doi:10.3892/br.2015.417 · Cited by 41
“One previous meta-analysis by Noto et al (16), which included three studies, confirmed the association between metformin use and the reduction of the lung cancer risk among patients with T2DM (RR=0.67, 95% CI, 0.45‑0.99), which was contradictory to that of another meta-analysis based on four observational studies (RR=…”
ResultInfluentialArvind, A., Memel, Z. N., Philpotts, L. L., Zheng, H., Corey, K. E., & Simon, T. G. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154780 · Cited by 43
Vest, L. S., Koraishy, F. M., Zhang, Z., Lam, N. N., Schnitzler, M. A., Dharnidharka, V. R., Axelrod, D., Naik, A. S., Alhamad, T. A., Kasiske, B. L., et al. (2018) · Clinical Transplantation · doi:10.1111/ctr.13302 · Cited by 41
Unraveling the Peculiar Features of Mitochondrial Metabolism and Dynamics in Prostate Cancer
Fontana, F., Anselmi, M., & Limonta, P. (2023) · Cancers · doi:10.3390/cancers15041192 · Cited by 41
Martelli, A. M., Chiarini, F., Evangelisti, C., Ognibene, A., Bressanin, D., Billi, A. M., Manzoli, L., Cappellini, A., & McCubrey, J. A. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.694869 · Cited by 41
“Since then, these results have been confirmed in other studies [90-92], including a meta-analysis investigation [93].”
ResultPathways to improving combined modality therapy for stage III nonsmall-cell lung cancer
Schild, S. E., & Vokes, E. E. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv621 · Cited by 40
“Metformin use was found to be associated with a decrease in lung cancer incidence in patients with diabetes [47].”
BackgroundKashi, Z., Mahrooz, A., Kianmehr, A., & Alizadeh, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151543 · Cited by 41
“It inhibits hepatic glucose production, increases glucose uptake, suppresses the gastric absorption of glucose, and serves as an insulin sensitizer [4,6,7].”
BackgroundDrug Repurposing for the Treatment of Acute Myeloid Leukemia
Andresen, V., & Gjertsen, B. T. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00211 · Cited by 44
“Further, registry studies of diabetic patients on metformin have indicated reduced risk of pancreatic cancer (74).”
BackgroundInhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells
Du, J., Shi, H.-R., Ren, F., Wang, J.-L., Wu, Q., Li, X., & Zhang, R. (2017) · BMC Cancer · doi:10.1186/s12885-017-3840-1 · Cited by 41
Singh, A., Gu, J. J., Zhang, Q., Torka, P., Sundaram, S., Mavis, C. K., & Hernandez‐Ilizaliturri, F. J. (2020) · Cancer & Metabolism · doi:10.1186/s40170-020-00213-w · Cited by 41
Progress in Research of Nanotherapeutics for Overcoming Multidrug Resistance in Cancer
Maimaitijiang, A., He, D., Li, D., Li, W., Su, Z., Fan, Z., & Li, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25189973 · Cited by 38
“These traits facilitate their adaptation to stress and enable them to resume growth after treatment.”
BackgroundLettieri‐Barbato, D., Vegliante, R., Desideri, E., & Ciriolo, M. R. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.02.003 · Cited by 42
Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal Cancer
Paulus, J. K., Williams, C. D., Cossor, F. I., Kelley, M. J., & Martell, R. E. (2016) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0312 · Cited by 38
Yarmolinsky, J. W., Bouras, E., Constantinescu, A., Burrows, K., Bull, C. J., Vincent, E. E., Martin, R. M., Dimopoulou, O., Lewis, S. J., Moreno, V. R., et al. (2023) · Diabetologia · doi:10.1007/s00125-023-05925-4 · Cited by 42
Metformin: From diabetes to cancer to prolongation of life
Sirtori, C. R., Castiglione, S., & Pavanello, C. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107367 · Cited by 40
Walker, E. J., Ko, A. H., Holly, E. A., & Bracci, P. M. (2014) · International Journal of Cancer · doi:10.1002/ijc.29120 · Cited by 39
Anti-tumor effects of metformin on head and neck carcinoma cell lines: A systematic review
Rêgo, D. F., Elias, S. T., Amato, A. A., Canto, G. D. L., & Guerra, E. N. S. (2016) · Oncology Letters · doi:10.3892/ol.2016.5526 · Cited by 38
“Metformin use in diabetic patients has been associated with decreased cancer incidence and mortality (21-23).”
Current state and outlook for drug repositioning anticipated in the field of ovarian cancer
Kobayashi, Y., Banno, K., Kunitomi, H., Tominaga, E., & Aoki, D. (2019) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2019.30.e10 · Cited by 42
“Epidemiological studies indicated that the cancerrelated mortality rate is significantly lower in patients taking metformin, and that survival rates and survival periods for many types of cancer, including colorectal, pancreatic, breast, liver, and endometrial cancers, have improved in such patients [40-42].”
Background
Metadata
- Authors
- Noto, H., Goto, A., Tsujimoto, T., & Noda, M.
- Affiliations
- National Center for Global Health and Medicine (JP)
- Corresponding author
- Noto, Hiroshi
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-03-20
- Volume
- 7
- Issue
- 3
- Pages
- e33411
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3308971
- OpenAlex
- W2040608814
- Cited by
- 566
- References
- 106
- Citations by year
- 2026: 16 · 2025: 15 · 2024: 20 · 2023: 29 · 2022: 28 · 2021: 33 · 2020: 41 · 2019: 38 · 2018: 28 · 2017: 50 · 2016: 60 · 2015: 57 · 2014: 60 · 2013: 65 · 2012: 25
- FWCI
- 6.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Ministry of Health, Labour and Welfare
- Japan Diabetes Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Oncology › Cancer Risks and Factors
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- metformin, diabetes mellitus, cancer risk, cancer mortality, cancer incidence, colorectal cancer, hepatocellular carcinoma, lung cancer, chemoprevention
- MeSH terms
- Clinical Trials as Topic, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin, Neoplasms, Risk Factors, Meta-Analysis as Topic, Incidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.